Sugi Predict

Sugi Predict / Compounds / SCHEMBL7362168

SCHEMBL7362168

SCHEMBL7362168

CC(C)C(=O)NC(C)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 7/20 0.52
▸ ACE P12821 2/20 0.52
▸ CPA1 P15085 1/20 0.52
▸ ACE2 Q9BYF1 1/20 0.52
▸ RAB9A P51151 1/20 0.42
▸ LTA4H P09960 3/20 0.42
▸ LMNA P02545 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ ANPEP P15144 1/20 0.39
▸ ECE1 P42892 1/20 0.39
▸ TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9652457 1.00 MME (0.52) MMEACECPA1ACE2RAB9A
SCHEMBL7725288 1.00 MME (0.52) MMEACECPA1ACE2RAB9A
SCHEMBL18098146 0.95 MME (0.48) MMEACECPA1ACE2RAB9A
SCHEMBL15307782 0.95 MME (0.48) MMEACECPA1ACE2RAB9A
SCHEMBL15080628 0.95 MME (0.48) MMEACECPA1ACE2RAB9A
SCHEMBL23432970 0.87 MME (0.43) MMEACECPA1ACE2RAB9A
SCHEMBL4572623 0.81 MME (0.50) MMEACECPA1ACE2RAB9A
SCHEMBL6374397 0.81 MME (0.50) MMEACECPA1ACE2RAB9A
SCHEMBL380600 0.79 DPP4 (0.52) MMEACECPA1ACE2RAB9A
SCHEMBL9698824 0.79 DPP4 (0.52) MMEACECPA1ACE2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112135812-B Ketamine derivatives and pharmaceutical compositions thereof 凯瑞康宁生物工程（武汉）有限公司 2022-01-18 — — CN claimed
EP-3710458-B1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2026-03-25 — — EP disclosed
EP-4681777-A2 PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF XWPharma Ltd. (KY) 2026-01-21 — — EP disclosed
EP-3737665-B1 PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF XWPHARMA LTD (KY) 2026-01-07 — — EP disclosed
US-12312370-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2025-05-27 — — US disclosed
US-20250122149-A1 KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF XWPharma Ltd. (KY) 2025-04-17 — — US disclosed
US-12209060-B2 Ketamine derivatives and compositions thereof XWPharma Ltd. (KY) 2025-01-28 — — US disclosed
CN-115677718-B Methyl methylamine derivative preparation, pharmaceutical composition and application thereof 武汉思瓴生物科技有限公司 2024-11-01 — — CN disclosed
US-20240199655-A1 Immunoproteasome Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-06-20 — — US disclosed
CN-111491938-B Immunoproteasome inhibitors 普林斯匹亚生物制药公司 2024-05-24 — — CN disclosed
US-8476224-B2 Macrocycles and their uses NOVARTIS AG (US) 2013-07-02 — — US disclosed
US-20110306649-A1 PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2011-12-15 — — US disclosed
WO-2010147776-A1 SUBSTITUTED -1,3,8-TRIAZASPIRO[4.5]DECANE-2,4-DIONES MERCK SHARP & DOHME CORP. (US) 2010-12-23 — — WO disclosed
US-7700591-B2 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors MERCK & CO., INC. (US) 2010-04-20 — — US disclosed
US-20090186830-A1 MACROCYCLES AND THEIR USES NOVARTIS AG (CH) 2009-07-23 — — US disclosed
US-20090186830-A1 MACROCYCLES AND THEIR USES NOVARTIS AG (CH) 2009-07-23 — — US disclosed
US-20070238723-A1 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors GOBLE STEPHEN D 2007-10-11 — — US disclosed
US-7259141-B2 Vancomycin analogs and methods thereof WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-08-21 — — US disclosed
US-7259141-B2 Vancomycin analogs and methods thereof WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-08-21 — — US disclosed
WO-1999052879-A1 ACYLRESORCINOL DERIVATIVES AS SELECTIVE VITRONECTIN RECEPTOR INHIBITORS AMERICAN HOME PRODUCTS CORPORATION (US) 1999-10-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209060-B2 Ketamine derivatives and compositions thereof OPRK1, KCNK10, KCNK17 MME 3500/4885ACE 1477/4885CPA1 4604/4885
US-20110306649-A1 PRODRUGS OF ION CHANNEL MODULATING COMPOUNDS AND USES THEREOF CACNA1B, CACNA1F, KCNN2 MME 2625/4885ACE 3869/4885CPA1 3024/4885
US-20240199655-A1 Immunoproteasome Inhibitors PSMC2, PSMB7, PSMB2 MME 188/4885ACE 111/4885CPA1 351/4885
US-12312370-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 MME 188/4885ACE 111/4885CPA1 351/4885
US-20090186830-A1 MACROCYCLES AND THEIR USES CYP11B2, OAT, CYP27A1 MME 1288/4885ACE 223/4885CPA1 2535/4885
US-20070238723-A1 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors CCR1, CCR2, CCRL2 MME 4040/4885ACE 1002/4885CPA1 653/4885
US-20250122149-A1 KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF OPRK1, KCNK10, KCNK17 MME 3500/4885ACE 1477/4885CPA1 4604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.